Pneumocystis Pneumonia Associated With Higher Mortality in Lung Transplants
Patients receiving lung transplants who had pneumocystis pneumonia had higher mortality rates than those without pneumocystis pneumonia.
Pneumonia
Recarbrio Approved for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The Food and Drug Administration has approved Recarbrio™ for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial.
Cefiderocol Gets Priority Review for Nosocomial Pneumonia
The FDA has granted Priority Review to cefiderocol for the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens.
ATS/IDSA Guideline Authors Offer Insight Into COVID-19–Related Pneumonia Management
The cochairs of ATS/IDSA Guideline for Treatment of Adults With Community-Acquired Pneumonia have published their perspectives of the guideline as it relates to the management of patients with COVID-19–related pneumonia.
Hydroxychloroquine Does Not Improve COVID-19 Pneumonia Outcomes
Hydroxychloroquine does not improve outcomes in COVID-19.
Trimethoprim-Sulfamethoxazole, Methotrexate Combination Treatment for P jirovecii Pneumonia
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
Imipenem/Relebactam/Cilastatin Noninferior to Pip/Tazo in Bacterial HAP, VAP
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
Different Phenotypes in COVID-19 Pneumonia Proposed
Patients with COVID-19 pneumonia may present with 2 distinct phenotypes, each warranting distinct treatments.
What Clinicians Need to Know About Influenza, Pneumococcal Vaccines in Rheumatic Diseases
Rheumatologists are recommended to have a working knowledge of vaccines for patients with rheumatic disease, and immunization must be individualized based on a shared decision-making process between the healthcare provider and patient.
Early Treatment With IV Immunoglobulin and LMWH May Improve COVID-19 Prognosis
Early initiation of intravenous immunoglobulin and low molecular weight heparin anticoagulant therapy may improve the prognosis of patients with severe COVID-19.
-
Loading...
-
Loading...
Next post in Lung Infection
